CCNL1 is a transcriptional regulator which participates in regulating the pre-mRNA splicing process. The protein seems to be involved in the regulation of RNA polymerase II (pol II). It functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. It may be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target:
The synthetic peptide sequence used to generate the antibody AP6610b was selected from the C-term region of human CCNL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
* VAT and and shipping costs not included. Errors and price changes excepted
